Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Cytek BioSciences (CTKB) stock in plain English

Free brief · no signupStart here
CTKBPublished Nov 19, 2026
Cytek BioSciences Inc
Healthcare · Medical Devices
Sells spectral flow cytometers and cell sorters that identify cell types using light emission profiles.
Assets:
Fremont and Wuxi facilitiesinstrument assembly and reagent manufacturing hubs
Aurora and Northern Lightscore spectral flow cytometry product lines
Amnis and Guava linesimaging cytometers acquired from Luminex
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

67
OPS ScoreOperating finances
Latest quote
+6.76%$6.32
$826.55M
n/a (loss)
$207.68M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 19, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was CTKB. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Cytek BioSciences (CTKB) do?

Cytek BioSciences Inc (CTKB) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Sells spectral flow cytometers and cell sorters that identify cell types using light emission profiles. Uses full spectrum profiling to capture the entire light signature of cells for biological research. It is worth $826.55M on the market and sold $207.68M over the last year.

Market cap
$826.55M
P/E ratio
None (reported a loss)
Annual sales
$207.68M
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 19, 2026

Brands and businesses behind CTKB

  • Cytek Aurora: Sells advanced spectral flow cytometer systems and cell sorting units to pharmaceutical and academic laboratories worldwide.
  • Amnis: Generates revenue by selling high-speed imaging flow cytometers that capture microscopic images of cells in suspension.
  • Guava: Sells compact, microcapillary flow cytometers and associated consumable assays for routine cell counting and health monitoring.
  • Northern Lights: Earns revenue through mid-range spectral cytometers tailored for standard laboratory diagnostics and basic research applications.

CTKB’s flags, in plain English

Each flag is a number from Cytek BioSciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.

Stupid Cash

Can pay this year's bills 4.5 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 10% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Still Climbing

Sales up 16.8% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Burning Cash

Losing money, profit margin of -39.1%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about CTKB

How big is Cytek BioSciences?

Cytek BioSciences’ market cap is $826.55M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $207.68M: what customers paid the company over the last year, before any costs.

What is CTKB’s P/E ratio?

CTKB has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with CTKB?

A large portion of revenue depends on academic institutions and biotechnology firms that cut equipment spending during funding droughts. That is one risk on Cytek BioSciences’ card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Cytek BioSciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. CTKB’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card